Iron, oxygen, and the pulmonary circulation

Matthew C. Frise and Peter A. Robbins

Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom

Submitted 2 March 2015; accepted in final form 5 June 2015

Frise MC, Robbins PA. Iron, oxygen, and the pulmonary circulation. J Appl Physiol 119: 1421–1431, 2015. First published June 11, 2015; doi:10.1152/japplphysiol.00179.2015.—The human pulmonary vasculature vasoconstricts in response to a reduction in alveolar oxygen tension, a phenomenon termed hypoxic pulmonary vasoconstriction (HPV). This review describes the time course of this behavior, which occurs in distinct phases, and then explores the importance for HPV of the hypoxia-inducible factor (HIF) pathway. Next, the HIF-hydroxylase enzymes that act as molecular oxygen sensors within the HIF pathway are discussed. These enzymes are particularly sensitive to intracellular iron availability, which confers iron-sensing properties on the HIF pathway. Human studies of iron chelation and supplementation are then reviewed. These demonstrate that the iron sensitivity of the HIF pathway evident from in vitro experiments is relevant to human pulmonary vascular physiology. Next, the importance of iron status in high-altitude illness and chronic cardiopulmonary disease is explored, and the therapeutic potential of intravenous iron discussed. The review concludes by highlighting some further complexities that arise from interactions between the HIF pathway and other intracellular iron-sensing mechanisms.

Iron; hypoxia; hypoxic pulmonary vasoconstriction; hypoxia-inducible factor; high-altitude illness

“Since life’s addiction to iron transcends the oxygenation of the Earth’s atmosphere, living things must be protected from the potentially dangerous mix of iron and oxygen. The human being possesses grams of this potentially toxic transition metal, which is shuttling through his oxygen-rich humor” (77).

THIS MINI-REVIEW is concerned with the way in which iron and oxygen interact in the setting of the pulmonary circulation. Even a brief glance at the literature reveals frequent references to the reactivity of iron and oxygen and how dangerous they can be in combination. Nevertheless, many key cellular and physiological processes rely on their successful interaction. Most obviously, the oxygen-transport properties of hemoglobin depend on the binding of oxygen to ferrous iron within heme. Within the mitochondrion, iron is an essential component of several subunits of the electron transport chain. Furthermore, many members of a large family of enzymes, the 2-oxoglutarate-dependent dioxygenases—recognized, inter alia, as central to cellular hypoxia sensing—also use ferrous iron as a cofactor.

The erythropoietic response to hypobaric hypoxia helpfully demonstrates one link between iron and oxygen in physiology. Over a century ago, the striking relationship between hematocrit and altitude of residence was demonstrated by Mabel FitzGerald, who made careful measurements in individuals residing over a range of elevations as part of the Pike’s Peak expedition (25). What underlies this relationship? Alveolar hypoxia as a consequence of the fall in atmospheric pressure with ascent leads to arterial hypoxemia. Interstitial fibroblasts of the kidney respond to the fall in oxygen content of the blood and secrete erythropoietin, stimulating erythrocytosis, which requires the supply of large amounts of iron for new red blood cells. The resulting increase in hematocrit restores tissue oxygen delivery to a degree, but brings with it a need for more iron. Remarkably, it is not a fall in circulating iron levels that is the initial signal for the body to absorb more iron from the gut and liberate iron stores (90); it is hypoxemia itself via an as yet incompletely characterized, bone marrow-dependent pathway, which suppresses the iron-regulatory hormone hepcidin (31, 45, 50). In this setting, hypoxia signifies to the body that there is an impending iron requirement. A low-oxygen signal is translated as a low-iron signal. Given that expansion of the circulating red blood cell mass is a huge sink for iron, the advantages of this arrangement are clear. However, as shall be discussed, it also turns out to be the case that the converse is true: iron deficiency generates a hypoxia signal, with wide-ranging implications for human physiology, particularly high-altitude physiology, and many human diseases.

Glossary

| Term          | Definition                                      |
|---------------|-------------------------------------------------|
| AMS           | Acute mountain sickness                         |
| CHF           | Chronic heart failure                           |
| CO            | Cardiac output                                  |
| COPD          | Chronic obstructive pulmonary disease           |
| CMS           | Chronic mountain sickness                       |

http://www.jappl.org  Licensed under Creative Commons Attribution CC-BY 3.0: © the American Physiological Society. ISSN 8750-7587. 1421
MEASURING THE RESPONSE OF THE PULMONARY CIRCULATION TO HYPOXIA

Nearly a century ago, Haldane recognized that the lungs ought to employ a mechanism to match delivery of deoxygenated blood to well-ventilated lung regions (35). Two decades later, the phenomenon of hypoxic pulmonary vasoconstriction (HPV) was demonstrated in anesthetized cats (96) and subsequently in humans (57, 101). While the role of HPV in determining regional pulmonary blood flow at rest in healthy humans continues to be the subject of investigation (7, 8, 22), what is certain is that the pulmonary vasculature has been changed in some way as a consequence of this sustained hypoxic stimulus, since if a further hypoxic challenge is delivered while euoxic PASP remains elevated, the resulting acute response is more marked: acclimatization has occurred.

Further temporal resolution of the early stages of HPV has been provided using an end-tidal forcing system and transthoracic echocardiography (88). With the onset of alveolar hypoxia, a first phase of HPV is rapidly detectable and becomes maximal within a few minutes (Fig. 1B); following this initial brisk response, a second phase can be demonstrated after ~40 min (Fig. 1C). If the pulmonary vasculature is exposed to a brief hypoxic stimulus, less than or equal to the duration of the first phase of HPV (Fig. 1B), then on return to euoxic PASP quickly returns to preexposure levels. If the hypoxic stimulus continues such that the second phase of HPV is manifest (Fig. 1, A and C), then it takes considerably longer for PASP to fall back to baseline levels (10, 23, 81, 88). The magnitude of this effect depends on the duration of hypoxia; when this extends beyond hours into days and weeks, pulmonary vascular remodeling occurs, such that inhalation of supplemental oxygen has little effect (32).

MECHANISMS UNDERLYING HPV: INSIGHTS FROM GENETIC ALTERATIONS OF OXYGEN SENSING

The underlying processes responsible for the mediation and modulation of HPV are the subject of intense research, and the literature on the subject is vast (58, 87). At the most fundamental level, HPV involves inhibition of oxygen-sensitive potassium channels, depolarization of pulmonary artery smooth muscle cells, and calcium influx through voltage-gated calcium channels causing vasoconstriction. Setting aside this immediate response of the pulmonary vasculature to alveolar hypoxia, the observation that the second phase of HPV brings with it a temporary change in the behavior of the pulmonary circulation suggests that alterations in gene expression may be important during this component of the pulmonary vascular response to hypoxia. An obvious candidate for orchestrating at
least some of this is the hypoxia-inducible factor (HIF) pathway (78).

The HIF pathway. HIF acts as a transcription factor at hypoxia-response element (HRE) sites in the genome when bound as a dimer consisting of one HIFα/HIFβ subunit (98). HREs regulate the expression of hundreds of genes including those involved in erythropoiesis, angiogenesis, and metabolism (44, 76). The HIF pathway provides cells with the machinery needed to sense and respond to changes in oxygen tension, since the HIFα protein is a target for hydroxylation at several amino acid residues by enzymes with an absolute requirement for dioxygen—prolyl-hydroxylase domain enzymes (PHDs) and an asparaginyl hydroxylase. Depending on the site of hydroxylation, HIFα is either tagged for polyubiquitination and proteasomal degradation, or, if it escapes this process, inhibited from recruiting coactivators required for promoter activity at HREs (44). Since these inhibitory effects rely on hydroxylation which in turn depends on the abundance of oxygen, hypoxia quickly leads to an increase in the intracellular level of HIFα, dimerization with HIFβ, and recruitment of the necessary cofactors to alter gene expression.

Animal models. Animal models illustrate well the central importance of HIF in regulating the hypoxic behavior of the pulmonary circulation. Mice heterozygous for deletion of HIF1α demonstrate attenuated physiological sequelae of alveolar hypoxia (105), with delayed polycythemia, pulmonary hypertension, and right ventricular hypertrophy. Animals heterozygous for deletion of HIF2α are similarly protected, and do not show the sizeable increases in pulmonary expression of endothelin-1 or the rise in plasma catecholamine concentration, both of which are evident during prolonged hypoxia in wild-type littermates (18). Additionally, mice heterozygous for a gain-of-function mutation that activates HIF2α (initially identified in patients with unexplained erythrocytosis) develop pulmonary hypertension under euoxia in a gene dose-dependent manner (92). In terms of the importance of the HIF pathway for ventilation, mice heterozygous for deficiency of PHD2 (one of three closely-related PHD enzymes) demonstrate enhanced ventilatory sensitivity to acute hypoxia, similar to that seen in wild-type animals exposed to sustained hypoxia for a week in whom acclimatization has occurred. Enlargement of the carotid bodies is also a feature of these animals (16).

Chuvash polycythemia: upregulated hypoxia sensing exemplified. A rare human genetic condition, Chuvash polycythemia (CP), provides a striking demonstration of the importance of the HIF pathway. When either of two specific proline residues in HIFα is hydroxylated, this permits binding of the von Hippel-Lindau protein (VHL), an essential step in the process leading to proteasomal degradation of HIFα (40, 41). Patients with CP are homozygous for a mutation leading to the production of a hypomorphic form of VHL which does not bind hydroxylated HIFα as strongly (5). Thus, at normal oxygen tensions, these individuals have a HIF system signaling hypoxia as a consequence of inappropriate HIFα stabilization. This condition is distinct from the von Hippel-Lindau familial cancer syndrome, an autosomal dominant condition characterized by a variety of malignancies, in which grossly disturbed hypoxia physiology is not a feature (26).
CP is characterized by polycythemia, pulmonary hypertension, and elevated ventilation at normal alveolar oxygen tensions. Exposure of individuals with CP to even mild degrees of alveolar hypoxia results in a marked increase in PASP (Fig. 2A) and ventilation (82). At oxygen tensions producing appreciable effects in healthy volunteers, CP patients demonstrate very profound responses; the rise in PASP is so great as to bring pressures close to those in the systemic circulation (Fig. 2B). Patients with CP are, therefore, similar in many ways to healthy individuals who have acclimatized after a prolonged period at altitude (83).

**Turning-down hypoxia sensing: advantageous at altitude?**

No human diseases characterized by a pathological downregulation of the HIF pathway have yet been identified. However, mutations affecting the pathway in this manner may be advantageous for populations resident at high altitude, for example by protecting against the exaggerated polycythemia and pulmonary hypertension seen in chronic mountain sickness (CMS).

Tibetans are one population living at altitude for a period of time sufficiently long for a selection pressure to have had an appreciable effect (64). The Tibetan Plateau has probably been inhabited for at least 25,000 years (2, 66), exposing this group to an inspired partial pressure of oxygen of around 80 mmHg. Very soon after genetic approaches were applied to this population, multiple single-nucleotide polymorphisms (SNPs) re-

---

**Fig. 2.** A and B: pulmonary vascular responses to mild (PETO₂/70 mmHg) and moderate (PETO₂/50 mmHg) isocapnic hypoxia in patients with Chuvash polycythemia. Control groups comprised healthy volunteers and patients with polycythemia rubra vera. ΔPmax increased by 11.5 mmHg in the Chuvash polycythemia group during mild hypoxia, compared with only 1.1 mmHg in the normal control group (P < 0.05). Moderate hypoxia stimulated a rise in ΔPmax of 35.3 vs. 6.1 mmHg, respectively (P < 0.001). C and D: PASP responses to acute isocapnic hypoxia before and after an 8-h exposure to sustained isocapnic hypoxia. Data are for 10 Tibetan and 10 Han Chinese volunteers. E and F: the effect of 8-h isocapnic hypoxia on the rise in PASP during an acute isocapnic hypoxic challenge, and the attenuating effect of intravenous iron. With a prior saline infusion, following 8-h hypoxia there is an elevated euoxic PASP and an exaggerated response to a 20-min hypoxic challenge. With a prior iron infusion, euoxic PASP is unaffected following 8-h hypoxia, and the response to an acute hypoxic challenge is only slightly augmented. The intravenous iron has all but abolished the acclimatization effect on the pulmonary circulation. All values are means; error bars represent SE. [Modified from Smith et al. (82), Petousi et al. (63), and Smith et al. (81) with permission.]
lated to the gene encoding HIF2α, known as EPAS1, were identified as having undergone positive selection (13, 103). HIF2α is one of three HIFα paralogues in humans. Sex-adjusted hemoglobin concentrations at altitude in Tibetan individuals homozygous for the major alleles were almost 1 g/dl lower than heterozygotes (13). A study of Tibetans living in the United Kingdom confirmed it was not just erythropoiesis that was affected; compared with a control group of Han Chinese individuals, Tibetans exhibited hypopreactivity of the pulmonary circulation in response to an acute (10-min) hypoxic challenge, as well as diminished acclimatization of the pulmonary vasculature during a sustained (8-h) hypoxic exposure (Fig. 2, C and D).

Interestingly, SNPs related to the gene EGLN1, which encodes PHD2, have also been identified as having undergone positive natural selection in the Tibetan population (80, 103) and are similarly associated with lower hematocrit at altitude. Presumably the effect of these genetic differences is opposite to that seen in CP patients, such that intracellular HIFα concentrations are lower, either as a result of reduced basal transcription of HIFα mRNA, or more rapid proteasomal degradation of the HIFα protein at a given oxygen tension. Recent work studying Tibetan individuals resident in the United States has provided evidence supporting the latter effect. Missense mutations in exon 1 of EGLN1 give rise to a PHD2 variant with a lower Km for oxygen (52). As a result, this mutant HIF-hydroxylase may promote increased HIFα hydroxylation and degradation compared with the wild-type enzyme, serving to “damp down” hypoxia signaling.

**INFLUENCING OXYGEN SENSING BY MANIPULATING IRON BIOAVAILABILITY**

The various genetic effects on canonical HIF pathway signaling described above, as well as others that have been identified (26, 49), must act by altering the relationship between oxygen tension and binding of functional HIFα-HIFβ dimers to HREs. There is considerable interest in pharmacological manipulation of the HIF-hydroxylases (59), particularly in the production of therapeutic inhibitors of PHDs. One application is in the treatment of anemia resulting from chronic renal disease. In patients with fibrotic kidneys who are receiving hemodialysis, endogenous erythropoietin production can be greatly augmented using a small molecule PHD inhibitor, implicating disordered oxygen sensing, rather than simply loss of erythropoietin production capacity, in the etiology of renal anemia (15). Aside from this avenue of investigation, the question arises as to whether there may be biological factors that disturb the relationship between oxygen tension and HIFα protein activity. One such factor of particular interest is iron (56).

**HIF-hydroxylases and ferrous iron.** The HIF-hydroxylases are members of the 2-oxoglutarate and iron-dependent dioxygenase superfamily (51). The ferrous iron required as a cofactor in these enzymes was recognized as being particularly prone to displacement and oxidation, leading to the suggestion that HIF-hydroxylase activity was likely to be sensitive to intracellular iron availability (74). In vitro, iron chelation with desferrioxamine (DFO) induces HIF1 activity and erythropoietin mRNA expression with a similar time course to hypoxia (97). This iron dependence may explain the long recognized hypoxia-mimetic effect of cobalt ions, including an erythropoietic effect in humans (14). It is possible that cobalt substitutes for the ferrous iron in HIF-hydroxylases, inhibiting them and stabilizing HIFα, although this has not been conclusively shown to occur in vivo, and several other possible mechanisms exist (54). Further in vitro studies have clearly demonstrated the marked sensitivity of PHD activity to intracellular iron availability (47, 61), although it remains difficult to prove directly that this is due to the requirement of these enzymes for ferrous iron as a cofactor, as opposed to an effect on intracellular redox status, for example.

**Human laboratory studies of iron depletion and supplementation.** In studies of healthy human volunteers, DFO infusion was shown to increase serum erythropoietin under euoxic conditions in a dose-dependent fashion (67) as well as elevating euoxic PASP (10), the latter effect with a very similar time course to HPV. The response of the pulmonary vasculature to an acute hypoxic challenge is also considerably enhanced following a prolonged infusion of DFO (81). The clinical management of patients with CP includes venesection to reduce hematocrit, which provides an opportunity to examine the effects of iron depletion on oxygen sensing. Studies of peripheral blood mononuclear cells from CP patients with low ferritin suggest that iron deficiency does have a significant effect on HIF-target gene expression, albeit in this unusual setting where HIFα is constitutively stabilized (106).

Conversely, increasing iron bioavailability to supraphysiological levels in healthy humans using intravenous iron diminishes HPV (81). In this study, brief hypoxic challenges were employed to measure the responsiveness of the pulmonary circulation before and after a period of acclimatization induced by a long hypoxic exposure. After an 8-h period of eucapnic hypoxia, healthy volunteers demonstrated an increase in euoxic PASP and an exaggerated response to the acute hypoxic challenge compared with before the exposure. As Fig. 2, E and F, illustrates, when intravenous iron was given in advance of the hypoxic acclimatization period, the usual elevation in euoxic PASP was abolished and the response to the acute hypoxic challenge was only slightly greater than at the outset (81).

Following intravenous iron, the time course of the progressive rise in PASP during the long hypoxic exposure, as shown in Fig. 3, is also fundamentally different (89). It is as if intravenous iron abolishes the second phase of HPV, along with its consequences for the subsequent behavior of the pulmonary vasculature on return to euoxia, while having very little, if any, effect on the first phase of HPV. In some respects, intravenous iron loading causes the response of the pulmonary vasculature to hypoxia to resemble that observed in Tibetans (27), further supporting the hypothesis that iron is acting through HIF in these human studies.

Although there is good reason for believing that the effects of iron described here are mediated via actions on the HIF pathway, the human studies described above are not a direct proof. For example, large doses of intravenous iron may have an effect on HPV via HIF-independent mechanisms, such as a direct effect on potassium channels from free radical generation. A further study in our laboratory suggests, however, that HPV may be attenuated chronically using repeated small doses of intravenous iron to elevate body iron stores, to a similar magnitude as when one large dose is given (Bart NK, unpub-
lished observations). This finding would not be in keeping with an effect mediated by high serum non-transferrin-bound iron levels. Direct evidence that iron deficiency elevates HIF in the lung is provided by the finding that rats fed a profoundly iron-deficient diet show increased lung expression of HIF1α and HIF2α, and resultant upregulation of HIF-target genes (19). Moreover, pulmonary arterial hypertension and right ventricular hypertrophy develop in these animals, and these abnormalities are ameliorated by iron replacement. Candidate human HIF-regulated genes that may contribute to the development of hypoxic pulmonary hypertension include those coding for endothelin, voltage-gated potassium channels, transient receptor potential calcium channels, and the sodium-hydrogen antiporter (75). Figure 4 gives an overview of the putative action of iron deficiency on the pulmonary vasculature, mediated by the HIF pathway.

Human studies in the field. The work described so far was conducted under laboratory conditions and employed eucapnic normobaric hypoxia. Clearly there may be differences at altitude due not only to poikilocapnia but also because hypobaric hypoxia may have subtly different effects from normobaric hypoxia (55). A study in Peru (84) that took healthy individuals from sea level to 4,340 m and measured PASP over a week found, as expected, a significant rise in PASP induced by hypobaric hypoxia shortly after ascent. After 3 days at this elevation, individuals were randomized in a blinded fashion to receive either intravenous iron (200 mg iron-sucrose) or saline. Those given iron showed a significant fall in PASP by 4 h; overall ~40% of the pulmonary hypertensive response to hypobaric hypoxia was reversed by iron. Importantly, this effect was not simply evident during the phase of grossly elevated circulating iron levels (Fig. 5). This suggests that the effect of intravenous iron on the pulmonary circulation may be sustained for a sufficient length of time to make it useful clinically. More recent data from our laboratory support the view that the effects of a single dose of intravenous iron (ferric carboxymaltose 15 mg/kg; maximum 1 g) on HPV are sustained at a clinically relevant level for a period of weeks to months (Bart NK, unpublished observations).

Possible adverse effects of intravenous iron. One concern is that the doses of iron administered in these human physiology studies are large and may cause adverse effects from, for instance, free-radical generation. It is certainly the case that in patients with chronic renal failure given a single dose of intravenous iron (100 mg iron-sucrose), evidence of oxidative stress and transient proteinuria can be demonstrated (1). How-
ever, a study giving repeated doses of intravenous iron (200 mg iron-sucrose weekly for 5 wk) to patients with chronic heart failure, renal impairment, and iron-deficiency anemia, found that iron-loading in fact resulted in a fall in the inflammatory marker C-reactive protein and improved renal function (93).

This study, along with others in chronic cardiopulmonary disease that are discussed later, do not support the view that oxidative stress from intravenous iron administration translates into a clinically meaningful deleterious effect, although as newer intravenous iron preparations are increasingly used in clinical practice we can expect to accumulate more evidence in this regard.

**IRON AND HPV IN HIGH-ALTITUDE ILLNESS**

There is good reason to suspect that iron may be important in the pathogenesis of high-altitude illness (HAI). Individuals prone to high-altitude pulmonary edema (HAPE) exhibit, as a group, more potent HPV than those who are not HAPE-susceptible (33). One possibility is that differences in iron bioavailability contribute to this interindividual variation. The erythropoietic drive which results from ascent to altitude is a large sink for iron and this may induce iron deficiency as a consequence (69), even in the face of apparently adequate baseline iron stores. In Fig. 5 a fall in transferrin saturation can be observed over the first 3 days at high altitude in both groups, reflecting a change in the balance between iron supply and demand. A recent study has examined the relationship between serum iron, HAPE and the hormone hepcidin, which negatively regulates the availability of circulating iron (4). This study demonstrated an elevation of hepcidin associated with inflammation in HAPE, but failed to show any difference in serum iron between those with HAPE and those without. Whether or not iron status contributes to the pathogenesis of HAPE, a mechanism by which it could contribute to the “unevenness” of HPV—implicated in the pathogenesis of HAPE (12, 37)—is not immediately obvious.

With respect to acute mountain sickness (AMS), in a further study in Peru (91), healthy individuals who were rapidly transported from sea-level to 4,340 m had a smaller increase in Lake Louise score on the first day at high altitude if given iron before ascent. In patients with existing CMS, iron depletion induced by repeated venesection was associated with a gradual rise in PASP, although interestingly this was not immediately reversed by intravenous iron infusion (84).

Although a strong hypoxic pulmonary vasoconstrictor response may predispose to HAI, a strong hypoxic ventilatory drive may confer some protection. While the HIF-system may influence the magnitude of both responses, as is illustrated by patients with CP (82), in none of the human studies discussed so far has an effect of iron status been found on the ventilatory response to hypoxia. It is also of note that no correlation was evident between the magnitudes of these two responses in a study of early acclimatization in 80 individuals (24). There are of course many potential explanations, including different relative contributions of the two main HIF paralogues and differences in regulation of cellular iron homeostasis between the two systems.

**IRON AND THE PULMONARY CIRCULATION IN CHRONIC DISEASE**

Nutritional iron deficiency is extremely common worldwide, affecting perhaps two billion individuals (107). Additionally, in many chronic diseases a state of functional iron deficiency or iron sequestration exists; there are sufficient stores of iron in the body but these are inaccessible for the processes that require it, most obviously erythropoiesis. Inflammation, which elevates circulating levels of hepcidin, is a major etiological factor (28, 99). Given the prevalence of iron deficiency, even a small effect of iron status on oxygen sensing would be potentially significant for human health. Preliminary data from our laboratory suggest that iron deficiency in otherwise healthy individuals does indeed influence HPV (Frise MC, unpublished observations).

**Chronic heart failure and idiopathic pulmonary arterial hypertension.** Iron deficiency has received considerable attention in the setting of two chronic cardiopulmonary conditions: chronic heart failure (CHF) and pulmonary arterial hypertension. In CHF, iron deficiency is a strong predictor of mortality that is independent of anemia (46). In two large randomized-controlled trials, treating iron-deficient CHF patients with intravenous iron produced very significant improvements in functional outcomes independent of any effect on hemoglobin (6, 65). More recently, iron deficiency has been shown to predict death in patients following an episode of acute heart failure (43), again independently of anemia. Remarkably, any explanation for how iron deficiency confers this excess risk of mortality has been lacking. Iron has pleotropic functions in...
human biology, but disordered oxygen sensing appears to be one possibility.

In idiopathic pulmonary arterial hypertension (IPAH), iron deficiency is common (85) and correlates with hemodynamic measures (71) as well as WHO functional class (68). Here, mutations that disturb bone morphogenetic protein signaling underlie a significant proportion of cases, and this pathway is instrumental in iron homeostasis in its own right (94). A very small study has recently suggested intravenous iron therapy may be helpful in IPAH (95), and a much larger randomized-controlled clinical trial involving comprehensive clinical assessment of these individuals is also underway (39).

Chronic obstructive pulmonary disease. One condition with a very high global burden of morbidity and mortality, in which iron deficiency has received less attention, is chronic obstructive pulmonary disease (COPD). This disorder is of particular interest because inflammation, chronic hypoxemia, and hypoxia-driven pulmonary hypertension are all present. In view of this, a degree of iron deficiency would be expected, and additionally two small studies have suggested that anemia due to iron deficiency may be common in such patients (73, 79). A small controlled study from our laboratory has recently found that iron deficiency, even in the absence of anemia, is common in patients with COPD, and shows a complex association with inflammation and hypoxemia (60).

IRON-RESPONSIVE ELEMENTS: A FURTHER LINK BETWEEN IRON AND HIF

This review has focused on the HIF pathway as a potential mediator of the effects of iron upon oxygen-sensing behavior, particularly HPV. Indeed, given the iron dependence of the HIF-hydroxylases, the function of the HIF pathway could equally well be viewed as concerned with sensing and signaling levels of intracellular iron in a manner modulated by oxygen. However, intracellular responses to iron are also regulated through iron-responsive elements (IREs) and the proteins that bind to them (IRPs). Binding of iron to IRPs induces a conformation change that inhibits their interaction with IREs. Unlike HREs, which transcriptionally regulate gene expression, IREs are found in the 5' and 3'-untranslated regions of various mRNAs and exert translational control over a number of genes important in iron homeostasis. These include ferritin (9, 36), ferroportin (53), and divalent metal transporter 1 (34). Recently it was recognized that HIF2α mRNA contains an IRE in the 5'-region (72), although HIF1α does not. The effect of IRP1 binding to the IRE in HIF2α is inhibitory. The posttranslational control of HIF2α degradation and activity by HIF-hydroxylases, and the translational regulation of HIF2α protein synthesis by IRE-IRP, are two opposing regulatory mechanisms. Deletion of IRP1 in mice leads to splenomegaly and extramedullary hematopoiesis (102) since marked iron deficiency no longer constrains HIF2α translation. When these mice are fed an iron-deficient diet, erythropoiesis is paradoxically stimulated by augmented erythropoietin synthesis. Importantly from the perspective of this review, spontaneous pulmonary hypertension is a prominent feature in these animals (30). It is notable that none of the studies of the HIF or PHD2 knockout animal models discussed early on in this review (16, 18, 92, 105) specifically addressed the consequences for iron homeostasis of these genetic alterations, which may be relevant in their own right.

Further discussion of the complex interactions between the HIF and IRE-IRP systems is beyond the scope of this review. It is worth pointing out, however, that the in vitro and in vivo studies of iron chelation and supplementation collectively presented here do suggest that modulation of HIF-hydroxylase activity is the dominant mechanism through which iron affects HIF-regulated gene expression. For a more detailed discussion of these issues, the interested reader is directed to the accompanying article by Gassmann and Muckenthaler (29).

CONCLUSION

This mini-review has outlined a number of studies addressing the role of the HIF pathway in modulating HPV, and the manner in which it may be influenced by iron. There is much that is unknown, but the role of iron in this pathway is not only of physiological interest but real clinical significance.

ACKNOWLEDGMENTS

We apologize to those investigators whose work we are unable to cite owing to limitations of space.

GRANTS

Work in the authors’ laboratory is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Programme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. M. C. Frise is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/14/48/30828).

DISCLOSURES

P. A. R. has received funding from Vifor Pharma, the manufacturers of Ferinject®, an intravenous iron preparation, for research studies not presented in this review.

AUTHOR CONTRIBUTIONS

Author contributions: M. C. F. prepared figures; M. C. F. drafted manuscript; P. A. R. edited and revised manuscript; M. C. F. and P. A. R. approved final version of manuscript.

REFERENCES

1. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: 2279–2289, 2004.
2. Aldenderfer M. Peopling the Tibetan Plateau: insights from archaeology. High Alt Med Biol 12: 141–147, 2011.
3. Allemann Y, Sartori C, Lepori M, Pierre S, Melot C, Naeije R, Scherrer U, Maggiorini M. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol 279: H2013–H2016, 2000.
4. Altamura S, Bartsh P, Dehnert C, Maggiorini M, Weiss G, Theurl I, Muckenthaler MU, Maibaur H. Increased hepcidin levels in high-altitude pulmonary edema. J Appl Physiol (1985) 118: 292–298, 2015.
5. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sereguea AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Pritchard CC. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614–621, 2002.
6. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P. FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436–2448, 2009.
7. Araji TJ, Henderson AC, Dubowitz DJ, Levin DL, Friedman PJ, Buxton RB, Prisk GK, Hopkins SR. Hypoxic pulmonary vasconstriction does not contribute to pulmonary blood flow heterogeneity in
normoxia in normal supine humans. J Appl Physiol (1985) 106: 1057–1064, 2009.
8. Asadi AK, Sa RC, Kim NH, Theilmann RJ, Hopkins SR, Buxton RB, Prisk GK. Inhaled nitric oxide alters the distribution of blood flow in the healthy human lung, suggesting active hypoxic pulmonary vasoconstriction in normoxia. J Appl Physiol (1985) 118: 331–343, 2015.
9. Aziz N, Munro HN. Iron regulates ferritin mRNA translation through a segment of its 5′ untranslated region. Proc Natl Acad Sci USA 84: 478–482, 1987.
10. Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol 92: 2501–2507, 2002.
11. Balanos GM, Talbot NP, Robbins PA, Dorrington KL. Separating the direct effect of hypoxia from the indirect effect of changes in cardiac output on the maximum pressure difference across the tricuspid valve in healthy humans. Pflugers Arch 450: 372–380, 2005.
12. Bártscs P, Mairbaurl H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol (1985) 98: 1101–1110, 2005.
13. Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C, Li JC, Liang Y, McCormack M, Montgomery HE, Pan H, Robbins PA, Shianna KV, Tam SC, Tsering N, Veeramah KR, Wang W, Wharton J, Xie P, Weele ME, Xu Y, Xu Z, Yang L, Zaman MJ, Zhang L, Zhang X, Zhai Z, Zhong Y. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci USA 107: 11459–11464, 2010.
14. Berk L, Burchenal JH, Castle WB. Direct effect of hypoxia on normoxic pulmonary vasoconstriction in patients with or without anemia. N Engl J Med 240: 754–761, 1949.
15. Bernhardt WM, Wiesener MS, Sciglipta P, Chou J, Schmieder RE, Gunzler V, Eckardt KU. Identification of the iron-responsive untranslated region. J Biol Chem 275: 2501–2507, 2000.
16. Bishop T, Talbot NP, Turner PJ, Nicholls LG, Pascual A, Shianna KV, Tam SC, Tsering N, Veeramah KR, Wang W, Wharton J, Xie P, Weele ME, Xu Y, Xu Z, Yang L, Zaman MJ, Zhang L, Zhang X, Zhai Z, Zhong Y. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett 309: 309–316, 2001.
17. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 33: 1662–1666, 1999.
18. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PA, Peter JB, Cormellet R. Heterogeneous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction following prolonged hypoxia. J Clin Invest 111: 1519–1527, 2003.
19. Cotroneo E, Ashak A, Wang L, Wharton J, Dubois O, Bozorgi S, Busbridge M, Alavian KN, Wilkins MR, Zhao L. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Cardiovasc Res 63: 351–371, 2004.
20. Croft QP, Formenti F, Talbot NP, Lunn D, Robbins PA, Dorrington KL. Variations in alveolar partial pressure for carbon dioxide and oxygen have additive but non-synergistic acute effects on human pulmonary vasoconstriction. PLoS One 8: e67886, 2013.
21. Currie PJ, Seward JB, Chan KL, Fyle DA, Hagler DJ, Mair DD, Reeder GS, Nishimura RA, Tajik AJ. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6: 750–756, 1985.
22. Dorrington KL, Balanos GM, Talbot NP, Robbins PA. Extent to which pulmonary vascular responses to Pco2 and Po2 play a functional role within the healthy human lung. J Appl Physiol (1985) 108: 1084–1096, 2010.
23. Dorrington KL, Clar C, Young JD, Jonas M, Tansley JG, Robbins PA. Time course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia. Am J Heart Circ Physiol 273: H1126–H1134, 1997.
24. Fatemian M, Herigstad M, Croft QP, Formenti F, Cardenas R, Wheeler C, Smith TG, Friedmannova M, Dorrington KL, Robbins PA. Determinants of ventilation and pulmonary artery pressure during early acclimatization to hypoxia in humans. J Physiol 2015 Apr 22. doi:10.1113/JP200611. [Epub ahead of print]
25. Fitzgerald MP. The changes in the breathing and the blood at various high altitudes. Phil Trans Royal Soc B: Biol Sci 203: 351–371, 1913.
iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 35: 2468–2474, 2014.

43. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393–402, 2008.

44. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of ferricytochrome as an iron regulator of iron metabolism. Nat Genet 46: 678–684, 2014.

45. Klip IT, Comin-Colet J, Voors AA, Poniakowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentopy P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165: 575–582, 2013.

46. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistance-associated macrophage protein 1. Cancer Res 66: 2600–2607, 2006.

47. Lams CS, Borlaug BA, Kane GC, Enders FT, Rodheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 119: 2663–2670, 2009.

48. Lee FS, Percy MJ. The HIF pathway and erythropoiesis. Annu Rev Pathol 6: 165–192, 2011.

49. Liu Q, Davidoff O, Niss K, Haase VH. Oxygen-sensing by hypoxia-inducible factor regulates hepatic via erythropoietin-induced erythropoiesis. J Clin Invest 112: 1783–1784, 2004.

50. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4: 152–166, 2008.

51. Lorenzo FR, Huff C, Myllynmaki M, Olenczok B, Swierczek S, Tashi G, Gorkud V, Wuren T, Ri-Gi M, McClain DA, Khan TM, Koul PA, Guchhait P, Salama ME, Xing J, Semenza GL, Liberzon E, Wilson A, Simonov TS, Jorde LB, Kaelin WG Jr, Koivunen P, Prchal JT. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet 46: 952–956, 2014.

52. Lymboussaki A, Pignatti E, Montosi G, Garuti C, Haile DJ, Poizat G, Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol 115: 420–426, 2012.

53. Mole DR, Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 12: 445–458, 2010.

54. Motley HL, Cournand A, Werko L, Himmelstein A, Dresdale D. The influence of short periods of induced acute anoxia upon pulmonary artery pressures in man. Am J Physiol 150: 315–320, 1947.

55. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) 98: 390–403, 2005.

56. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, Schofield CJ. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12: 481–501, 2010.

57. Nickol AH, Frise MC, Cheng HY, McGahey A, McFadyen BM, Harris-Wright T, Bart NK, Curtis MK, Drakesmith H, Ratcliffe PJ, Robbins PA. A cross-sectional study for high-altitude adaptation in Tibet. Science 329: 72–75, 2010.

58. Smith TG, Talbot NP, Croft NP, Talbot NF, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 586: 5999–6005, 2008.

59. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamarra CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NF, Treacy M, Robbins PA. Mutation of von Hippel-Lindau tumour suppressor and human cardiovascular phenotype. PLoS Med 5: e290, 2006.

60. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 141: 325–334, 2008.

61. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, Leon-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 302: 1444–1450, 2009.

62. Soon E, Treacy CM, Teohmer MB, MacKenzie-Ross R, Manglam V, Busbridge M, Sinclair-McGarvie M, Arnold J, Sheares KK, Morrell NW, Pempe-Zaba J. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 66: 326–332, 2011.
Iron, Oxygen, and the Pulmonary Circulation • Frise MC et al. 1431

86. Stevenson JG. Comparison of several noninvasive methods for estimation of pulmonary artery pressure. J Am Soc Echocardiogr 2: 157–171, 1989.

87. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev 92: 367–520, 2012.

88. Talbot NP, Balanos GM, Dorrington KL, Robbins PA. Two temporal components within the human pulmonary vascular response to approximately 2 h of isocapnic hypoxia. J Appl Physiol (1985) 98: 1125–1139, 2005.

89. Talbot NP, Croft QP, Curtis MK, Turner BE, Dorrington KL, Robbins PA, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ: 24: 686–695, 2015.

90. Upton PD, Morrell NW. The transforming growth factor-beta-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol 98: 1262–1266, 2013.

91. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, Ten Freytag D, Rudolph TK, Baldus S, Rosenkranz S. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol 175: 233–239, 2014.

92. Frise MC et al.